JUN and prostate carcinoma: Higher levels of JUN, MXD1, and AQP3 were associated with a better OS, and each of the three genes was upregulated by deslanoside (Figure 5 and Figure 7), suggesting that JUN, MXD1, and AQP3 could mediate deslanoside’s anticancer effect in prostate cancer cells.